No worsening of fatigue or health-related quality of life with oral azacitidine maintenance in AML patients in remissionOctober 24, 2021AML
Allo-HSCT in CR1 beneficial for elderly AML patients with unfavorable or intermediate-risk cytogeneticsOctober 24, 2021AML
LDAC+venetoclax shows promise as frontline therapy in treatment-naive AML patients unfit for IC October 24, 2021AML
R/R AML: Mito-FLAG improves response, but allo-HSCT remains essential for prolonged survivalOctober 24, 2021AML
Intensification of induction II does not improve outcomes in pediatric high-risk AMLOctober 24, 2021AML
Addition of quizartinib to LDAC improves outcomes in older patients with FLT3-ITD-mutated AMLOctober 24, 2021AML
AML: Better outcomes in children vs. adolescents, postadolescents and young adults after first allo-HSCTSeptember 26, 2021AML
ROM/AZA therapy shows promise in high-risk AML patients unsuitable for intensive chemotherapySeptember 26, 2021AML
Similar outcomes in AML patients undergoing allo-HSCT with MMUD, UCB, or Haplo donorsSeptember 26, 2021AML
